Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations
Identifieur interne : 002722 ( Main/Corpus ); précédent : 002721; suivant : 002723Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations
Auteurs : Bonnie P. Hersh ; Nancy L. Earl ; Robert A. Hauser ; Mark StacySource :
- Movement Disorders [ 0885-3185 ] ; 2010-05-15.
English descriptors
- KwdEn :
Abstract
We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE‐PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2–24 mg/day) versus placebo in patients with moderate‐to‐advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in “off” time (adjusted mean treatment difference [AMTD] – 0.7 hours; 95% confidence interval [CI], –1.1, –0.2; P = 0.0029), and “on” time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, –3.1; 95%CI, –4.4, –1.8; P < 0.0001), activities of daily living score (AMTD, –1.1; 95%CI, –1.7, –0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once‐daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23040
Links to Exploration step
ISTEX:60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations</title><author><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P." last="Hersh">Bonnie P. Hersh</name><affiliation><mods:affiliation>Department of Neurology, Harvard Vanguard Medical Associates, Boston Massachusetts, USA</mods:affiliation></affiliation></author><author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name><affiliation><mods:affiliation>Division of Neurology, Department of Medicine, Duke University, Durham, North Carolina, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23040</idno><idno type="url">https://api.istex.fr/document/60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002722</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations</title><author><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P." last="Hersh">Bonnie P. Hersh</name><affiliation><mods:affiliation>Department of Neurology, Harvard Vanguard Medical Associates, Boston Massachusetts, USA</mods:affiliation></affiliation></author><author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name><affiliation><mods:affiliation>Division of Neurology, Department of Medicine, Duke University, Durham, North Carolina, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-05-15">2010-05-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="927">927</biblScope><biblScope unit="page" to="931">931</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2</idno><idno type="DOI">10.1002/mds.23040</idno><idno type="ArticleID">MDS23040</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>Unified Parkinson's Disease Rating Scale</term><term>efficacy</term><term>motor fluctuations</term><term>ropinirole prolonged release</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE‐PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2–24 mg/day) versus placebo in patients with moderate‐to‐advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in “off” time (adjusted mean treatment difference [AMTD] – 0.7 hours; 95% confidence interval [CI], –1.1, –0.2; P = 0.0029), and “on” time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, –3.1; 95%CI, –4.4, –1.8; P < 0.0001), activities of daily living score (AMTD, –1.1; 95%CI, –1.7, –0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once‐daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Bonnie P. Hersh MD</name><affiliations><json:string>Department of Neurology, Harvard Vanguard Medical Associates, Boston Massachusetts, USA</json:string></affiliations></json:item><json:item><name>Nancy L. Earl MD</name><affiliations><json:string>Department of Clinical Neurosciences, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</json:string></affiliations></json:item><json:item><name>Robert A. Hauser MD</name><affiliations><json:string>Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item><json:item><name>Mark Stacy MD</name><affiliations><json:string>Division of Neurology, Department of Medicine, Duke University, Durham, North Carolina, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>efficacy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>motor fluctuations</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>ropinirole prolonged release</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Unified Parkinson's Disease Rating Scale</value></json:item></subject><articleId><json:string>MDS23040</json:string></articleId><language><json:string>eng</json:string></language><abstract>We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE‐PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2–24 mg/day) versus placebo in patients with moderate‐to‐advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in “off” time (adjusted mean treatment difference [AMTD] – 0.7 hours; 95% confidence interval [CI], –1.1, –0.2; P = 0.0029), and “on” time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, –3.1; 95%CI, –4.4, –1.8; P > 0.0001), activities of daily living score (AMTD, –1.1; 95%CI, –1.7, –0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once‐daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>6.98</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1111</abstractCharCount><pdfWordCount>14263</pdfWordCount><pdfCharCount>95853</pdfCharCount><pdfPageCount>26</pdfPageCount><abstractWordCount>165</abstractWordCount></qualityIndicators><title>Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations</title><genre><json:string>article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>6</total><last>931</last><first>927</first></pages><issn><json:string>0885-3185</json:string></issn><issue>7</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.23040</json:string></doi><id>60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: BH has received research support, honoraria, and consulting fees from GlaxoSmithKline. Nancy Earl is a former employee and shareholder at GlaxoSmithKline. Robert Hauser has received funds for speaking and consulting from GlaxoSmithKline. Duke University has received research and unrestricted educational grant funding attributed to Dr. Stacy from Allergan, Ceregene, Eisai, Merck, NIH, Novartis, Parkinson Study Group, Solvay, and Schering‐Plough.</note><note>GlaxoSmithKline and SkyePharma</note><note>GlaxoSmithKline</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations</title><author><persName><forename type="first">Bonnie P.</forename><surname>Hersh</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Harvard Vanguard Medical Associates, Boston 133 Brookline Ave, MA 02215</p></note><affiliation>Department of Neurology, Harvard Vanguard Medical Associates, Boston Massachusetts, USA</affiliation></author><author><persName><forename type="first">Nancy L.</forename><surname>Earl</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Clinical Neurosciences, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</affiliation></author><author><persName><forename type="first">Robert A.</forename><surname>Hauser</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation></author><author><persName><forename type="first">Mark</forename><surname>Stacy</surname></persName><roleName type="degree">MD</roleName><affiliation>Division of Neurology, Department of Medicine, Duke University, Durham, North Carolina, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-05-15"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="927">927</biblScope><biblScope unit="page" to="931">931</biblScope></imprint></monogr><idno type="istex">60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2</idno><idno type="DOI">10.1002/mds.23040</idno><idno type="ArticleID">MDS23040</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE‐PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2–24 mg/day) versus placebo in patients with moderate‐to‐advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in “off” time (adjusted mean treatment difference [AMTD] – 0.7 hours; 95% confidence interval [CI], –1.1, –0.2; P = 0.0029), and “on” time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, –3.1; 95%CI, –4.4, –1.8; P < 0.0001), activities of daily living score (AMTD, –1.1; 95%CI, –1.7, –0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once‐daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>efficacy</term></item><item><term>motor fluctuations</term></item><item><term>Parkinson's disease</term></item><item><term>ropinirole prolonged release</term></item><item><term>Unified Parkinson's Disease Rating Scale</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-04-22">Received</change><change when="2010-01-18">Registration</change><change when="2010-05-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="70"><doi origin="wiley" registered="yes">10.1002/mds.v25:7</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">7</numbering></numberingGroup><coverDate startDate="2010-05-15">15 May 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="170" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23040</doi><idGroup><id type="unit" value="MDS23040"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2009-04-22"></event><event type="manuscriptRevised" date="2009-11-14"></event><event type="manuscriptAccepted" date="2010-01-18"></event><event type="firstOnline" date="2010-03-29"></event><event type="publishedOnlineFinalForm" date="2010-05-05"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2010-03-29"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.5.2 mode:FullText" date="2011-08-12"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">927</numbering><numbering type="pageLast">931</numbering></numberingGroup><correspondenceTo>Harvard Vanguard Medical Associates, Boston 133 Brookline Ave, MA 02215</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23040.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="10"></count><count type="wordTotal" number="2954"></count></countGroup><titleGroup><title type="main" xml:lang="en">Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations<link href="#fn1"></link></title><title type="short" xml:lang="en">Ropinirole Prolonged Release: Early Efficacy</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Bonnie P.</givenNames><familyName>Hersh</familyName><degrees>MD</degrees></personName><contactDetails><email>bonnie_hersh@vmed.org</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Nancy L.</givenNames><familyName>Earl</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Robert A.</givenNames><familyName>Hauser</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Mark</givenNames><familyName>Stacy</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Harvard Vanguard Medical Associates, Boston Massachusetts, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Clinical Neurosciences, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Division of Neurology, Department of Medicine, Duke University, Durham, North Carolina, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">efficacy</keyword><keyword xml:id="kwd2">motor fluctuations</keyword><keyword xml:id="kwd3">Parkinson's disease</keyword><keyword xml:id="kwd4">ropinirole prolonged release</keyword><keyword xml:id="kwd5">Unified Parkinson's Disease Rating Scale</keyword></keywordGroup><fundingInfo><fundingAgency>GlaxoSmithKline and SkyePharma</fundingAgency></fundingInfo><fundingInfo><fundingAgency>GlaxoSmithKline</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE‐PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2–24 mg/day) versus placebo in patients with moderate‐to‐advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in “off” time (adjusted mean treatment difference [AMTD] – 0.7 hours; 95% confidence interval [CI], –1.1, –0.2; <i>P</i> = 0.0029), and “on” time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; <i>P</i> = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, –3.1; 95%CI, –4.4, –1.8; <i>P</i> < 0.0001), activities of daily living score (AMTD, –1.1; 95%CI, –1.7, –0.5; <i>P</i> = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once‐daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: BH has received research support, honoraria, and consulting fees from GlaxoSmithKline. Nancy Earl is a former employee and shareholder at GlaxoSmithKline. Robert Hauser has received funds for speaking and consulting from GlaxoSmithKline. Duke University has received research and unrestricted educational grant funding attributed to Dr. Stacy from Allergan, Ceregene, Eisai, Merck, NIH, Novartis, Parkinson Study Group, Solvay, and Schering‐Plough.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Ropinirole Prolonged Release: Early Efficacy</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations</title></titleInfo><name type="personal"><namePart type="given">Bonnie P.</namePart><namePart type="family">Hersh</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Harvard Vanguard Medical Associates, Boston Massachusetts, USA</affiliation><description>Correspondence: Harvard Vanguard Medical Associates, Boston 133 Brookline Ave, MA 02215</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nancy L.</namePart><namePart type="family">Earl</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Clinical Neurosciences, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert A.</namePart><namePart type="family">Hauser</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mark</namePart><namePart type="family">Stacy</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Division of Neurology, Department of Medicine, Duke University, Durham, North Carolina, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-05-15</dateIssued><dateCaptured encoding="w3cdtf">2009-04-22</dateCaptured><dateValid encoding="w3cdtf">2010-01-18</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="references">10</extent><extent unit="words">2954</extent></physicalDescription><abstract lang="en">We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE‐PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2–24 mg/day) versus placebo in patients with moderate‐to‐advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in “off” time (adjusted mean treatment difference [AMTD] – 0.7 hours; 95% confidence interval [CI], –1.1, –0.2; P = 0.0029), and “on” time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, –3.1; 95%CI, –4.4, –1.8; P < 0.0001), activities of daily living score (AMTD, –1.1; 95%CI, –1.7, –0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once‐daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: BH has received research support, honoraria, and consulting fees from GlaxoSmithKline. Nancy Earl is a former employee and shareholder at GlaxoSmithKline. Robert Hauser has received funds for speaking and consulting from GlaxoSmithKline. Duke University has received research and unrestricted educational grant funding attributed to Dr. Stacy from Allergan, Ceregene, Eisai, Merck, NIH, Novartis, Parkinson Study Group, Solvay, and Schering‐Plough.</note><note type="funding">GlaxoSmithKline and SkyePharma</note><note type="funding">GlaxoSmithKline</note><subject lang="en"><genre>Keywords</genre><topic>efficacy</topic><topic>motor fluctuations</topic><topic>Parkinson's disease</topic><topic>ropinirole prolonged release</topic><topic>Unified Parkinson's Disease Rating Scale</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>927</start><end>931</end><total>6</total></extent></part></relatedItem><identifier type="istex">60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2</identifier><identifier type="DOI">10.1002/mds.23040</identifier><identifier type="ArticleID">MDS23040</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002722 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002722 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2
|texte= Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations
}}
| This area was generated with Dilib version V0.6.23. |  |